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Abstract
Background: Anaemia is common in malaria. It is important to quantitate the risk of anaemia and to distinguish
factors related to the natural history of disease from potential drug toxicity.
Methods: Individual-patient data analysis based on nine randomized controlled trials of treatments of uncomplicated
falciparum malaria from 13 sub-Saharan African countries. Risk factors for reduced haemoglobin (Hb) concentrations
and anaemia on presentation and after treatment were analysed using mixed effect models.
Results: Eight thousand eight hundred ninety-seven patients (77.0% <5 years-old) followed-up through 28 days
treated with artemisinin combination therapy (ACT, 90%, n = 7968) or non-ACT. At baseline, under 5’s had the highest
risk of anaemia (77.6% vs. 32.8%) and higher parasitaemia (43,938 μl) than older subjects (2784 μl). Baseline anaemia
increased the risk of parasitological recurrence.
Hb began to fall after treatment start. In under 5’s the estimated nadir was ~35 h (range 29–48), with a drop of −12.8%
from baseline (from 9.8 g/dl to 8.7 g/dl, p = 0.001); in under 15’s, the mean Hb decline between day 0–3 was −4.7%
(from 9.4 to 9.0 g/dl, p = 0.001). The degree of Hb loss was greater in patients with high pre-treatment Hb and
parasitaemia and with slower parasite reduction rates, and was unrelated to age. Subsequently, Hb increased
linearly (+0.6%/day) until day 28, to reach +13.8% compared to baseline.
Severe anaemia (<5 g/dl, 2 per 1000 patients) was transient and all patients recovered after day 14, except one
case of very severe anaemia associated with parasite recurrence at day 28.
There was no systematic difference in Hb concentrations between treatments and no case of delayed anaemia.
Conclusion: On presentation with acute malaria young children with high parasitaemia have the highest risk of
anaemia. The majority of patients experience a drop in Hb while on treatment as early as day 1–2, followed by a
linear increase through follow-up. The degree of the early Hb dip is determined by pre-treatment parasitaemia
and parasite clearance rates. Hb trends and rick of anaemia are independent of treatment.
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Background
As anaemia is a common occurrence in malaria, it is often
difficult, in treated patients, to disentangle disease from
drug effects. Malaria anaemia has both central (decreased
red cell production) and peripheral causes (haemolysis,
phagocytosis of infected and uninfected erythrocytes)
[1, 2]. Artemisinin-based Combination Therapy (ACT) -
the treatment of choice for uncomplicated Plasmodium
falciparum malaria [3] - is generally safe and well-tolerated,
but anaemia remains a potential concern, in particular for
artemisinin derivatives. In vitro experiments point to inter-
ference with erythropoiesis at the proerythroblast and baso-
philic erythroblast stage [4]. In humans, acute delayed
haemolytic anaemia has been reported following artesunate
injections in severe malaria [5], but not with ACT in un-
complicated falciparum malaria; transient anaemia has been
reported in uncomplicated malaria after administration of
artesunate, alone or as part of ACT [6–11], with a dose-
dependent risk [12]. As safety in general, and laboratory
data in particular, are under-reported in antimalarial drug
trials, limited information can be derived from aggregated
data from the published literature. In particular anaemia,
even when monitored, is variably reported as a continuous
variable (haemoglobin concentration) or categorical vari-
able (using different thresholds and severity classes).
This group therefore joined to create an individual
participant-level database (IPD) of patients enrolled in
studies conducted in Sub-Saharan Africa and applied a
common, standardised analytical approach to quantify the
risk of anaemia in patients presenting with acute, uncom-
plicated falciparum malaria, and analysed the changes in
haemoglobin levels and anaemia status after treatment.
Methods
Data on age, parasitaemia, haemoglobin (Hb), treatment and
treatment outcome were extracted from primary data of
nine randomized controlled trials (RCT) conducted in sub-
Saharan Africa, of which seven had 28-day [13–20], and two
had 42-day follow-up [20, 21]. The RCTs included in this
paper were conducted to assess the efficacy and safety of
different malaria treatment in sub-Saharan Africa using the
WHO protocol (Zwang 2009, Zwang 2014). Data were cen-
sored when patients were lost to follow-up or had micros-
copy determined recurrent parasitaemia during follow-up.
Anaemia was defined and graded as per WHO, 2011
by age and sex [22] (Additional file 1: Table S1). Recovery
from anaemia was defined as Hb increasing to levels
above the aforementioned levels. Worsening of anaemia
was any increase at any time in the grade of severity com-
pared to pre-treatment (abnormal Hb in subjects with
normal pre-treatment value, or an abnormal value that
was of higher grade than pre-treatment). Drug-event rela-
tionship could not be attributed as it had not been
assessed systematically across the clinical trials.
Treatments were artesunate-amodiaquine (ASAQ, as
either fixed-dose or co-blister formulations) and compara-
tors including artemisinin combination therapy (ACT:
artemether-lumefantrine, AL; artesunate plus sulphadoxine/
pyrimethamine, AS + SP; dihydroartemisinin-piperaquine,
DP) or monotherapy (artesunate alone, AS; amodiaquine
alone, AQ) or non-artemisinin containing combinations
(AQ + SP).
Ethics
All trials were conducted according to the Helsinki
declaration and received approval by their respective
ethics committees. These analyses are in accordance with
the patient informed consent. Data were completely and
irreversibly anonymised at the source before being shared
and merged into the common database.
Statistical analysis
Categorical data (proportions of patients becoming or recov-
ering from anaemia) were compared using the chi-square or
the Fisher’s exact test. For non-normally distributed data
comparisons used the Mann-Whitney and the Kruskall-
Wallis tests and correlations, the Spearman test.
Definitions: D (Day) 0 = pre-treatment; HDRd1 (Hb
decrease rate) = percentage difference in Hb concentration
from D0 to D1; PRRd1 (parasite reduction rate) = percentage
difference in parasite density from D0 to D1; PCT (parasite
clearance time) = time to reach a negative malaria smear
for two consecutive days; nadir = the lowest Hb value at
any time on-study; Tn (time-to-nadir) = time at which the
nadir was reached for each study subject.
All available Hb values for every patient were considered
from D0 through D28. The risk of anaemia was assessed
by mixed-effect logistic regression model to account for
between-sites heterogeneity. The adjusted risks (AOR)
allowed for patients’ age, parasitaemia (log-transformed),
parasitological recurrence, treatment and trial.
The risk of Hb dropping, resulting in anaemia at D3,
or anaemia severity increasing, was analysed as a binary
variable by mixed-effect logistic regression models. The
percentage Hb decrease at nadir was analysed using
mixed-effect linear regression models. Hb trends from
D3 to D28 were assessed by a mixed-effect linear regres-
sion model and expressed as y = ax + b (were y, Hb; a,
slope; x, time; b, constant).
Confidence intervals were calculated at 95% (95%CI),
and comparisons considered significant when p < 0.05.
Data were analysed using Stata v13 (Stata Corp.).
Results
Analyses were based on 8897 patients, 89.6% treated with
an ACT and 10.4% with non-ACTs (Additional file 2:
Table S2, Additional file 3: Fig. S1), providing 38,864 Hb
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measurements (93% and 7% for ACT and non-ACT,
respectively).
Study characteristics are in Additional file 4: Table S3:
98% (n = 8728) of subjects had at least one other re-
corded value post-D0 (58% at D3, 80% at D7, 73% at
D28); 18% (n = 1645) children <5 years-old enrolled in
Liberia, Mozambique, Rwanda and Uganda had daily
measurements on D0 through D3; an additional 11%
(n = 1000) had daily measurements on D0 through D2.
All but two studies (Uganda and Rwanda) had at least
three measurements: D0, D28 and one in-between: D7
(11%, in four countries), D14 (20%, two countries), and
D3, D7, and D14 (17%, two countries).
Patients’ baseline characteristics by study are in Table 1
and Fig. 1: 77% were children <5 years of age, 24.1% were
5–11 years-old, 4.5% were 12–14 years-old, and 11.0% ≥15.
The geometric mean D0 parasite density was 13,790 over-
all, ranging from 594 (Liberia [19]) to 39,023 parasites/μl
(Mozambique [13]).
Anaemia and haemoglobin levels on presentation with
acute falciparum malaria
Sixty-seven percent (67.3%, n = 5978/8897) of subjects
had anaemia on D0, 63% mild or moderate. The mean
D0 Hb was 10.2 g/dl (standard deviation 2.05) and the
median 10.1 g/dl (range 3.4–18.3).
Hb increased with age (from a median of 9.6 g/dl
in < 5 years-old to 14.1 g/dl in males ≥15 years), corre-
sponding to a decreasing prevalence of anaemia (from
77.6% to 22.1%, respectively, Fig. 2).
A multivariate logistic regression model with mixed
effects found that the risk of D0 anaemia decreased sig-
nificantly with increasing age (p = 0.001 for all compar-
isons vs. under 5’s). Parasitological recurrence during
follow-up was more frequent in subjects with D0 an-
aemia (AOR 1.45, 95% CI 1.23–1.73, p = 0.001).
Overall, higher D0 parasite density correlated with lower
Hb by linear regression, mixed effect model (Fig. 3) except
for <5 year-olds who had higher D0 geometric mean para-
site densities (43,938 μl) than older subjects (2784 μl)
(Additional file 5: Fig. S2).
Anaemia during treatment and follow-up
Occurrence of anaemia
From D0 to last observation, 82.7% of the patients had
at least one Hb measurement fulfilling the anaemia criteria
(any grade of severity), corresponding to 26,408 (67.9%) of
the total 38,864 Hb measurements; of these, 20,430 (77.4%)
occurred after treatment start (D1-D28). Moderate or more
severe anaemia (≥grade 2) occurred in 47.6% of all mea-
surements (18,486/38,864), in 76.5% of episodes (14,148/
18,486) after treatment start (D1-D28). Post-D0 anaemia
was less frequent on ACT: all-grade (77.3% vs. 80.3%,
p = 0.036); ≥grade 2 anaemia (76.4% vs. 81.1%, p = 0.007).
Severity of anaemia
Five patients had very severe anaemia (grade 4) at D0.
Overall, 19 patients had 27 records of transient very
severe anaemia, corresponding to 2/1000 patients (19/
8897). All episodes of very severe anaemia occurred by
D14 in ACT groups, corresponding to 1 per 1000 (27/
26,408) of all anaemia episodes, with no difference
between treatments. Only one patient had very severe
anaemia on D28 concomitant with recurrent infection,
while all other patients recovered after D14. No case of
very severe anaemia was observed in patients treated
with non-ACT.
Changes in anaemia status
Of the 8720 patients with at least one additional post-D0
Hb measurement, 67.9% were anaemic on presentation
and 47.1% when last seen – the latter was composed of
41.9% who remained anaemic plus an additional 5.2%
who became anaemic post-D0. Anaemia grade worsened
in 31.9% patients.
Fig. 1 Flow chart
Zwang et al. BMC Infectious Diseases  (2017) 17:443 Page 3 of 10
Fig. 2 Boxplot of haemoglobin concentration values pre-treatment (D0) by age and sex category. The dotted blue line represents the anaemia-defining
Hb value for each category
Fig. 3 Scatter plot of haemoglobin concentration values and parasitaemia pre-treatment (D0): overall and by age and sex category. AOR for 5–11 years-
old of 0.51 (95% CI 0.41–0.62); 12–14 AOR 0.41 (0.28–0.60); ≥15 AOR 0.27 (0.20–0.37). For the whole study population the equation calculated by linear
regression with mixed effect model was y = − 0.06× + 10.3, p = 0.020
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Mixed-effect multivariate logistic regression model showed
an increased risk of anaemia worsening in patients with
higher D0 parasitaemia (AOR 1.65, 95% CI 1.52–1.79,
p = 0.001) and Hb (AOR 1.57, 95% CI 1.51–1.63,
p = 0.001), younger age (AOR 0.95, 95% CI 0.94–0.97,
p = 0.001, per year of age). It detected no significant
association with parasitological failure (AOR 0.94, 95% CI
0.81–1.12, p = 0.452) and no difference between treat-
ments, except a lower risk with AQ + SP (AOR 0.51,
95% CI 0.36–0.72, p = 0.001) compared to ASAQ.
Haemoglobin levels during treatment and follow-up
Haemoglobin levels changes (D0 – D3 – D28)
Ten countries and 15 sites (Burkina Faso, Gabon,
Liberia, Mali, Mozambique, Nigeria, Rwanda, Uganda,
Zambia, Zanzibar) had Hb measurements on D0, D3
and then weekly from D7-D28 (n = 4886 inclusive of the
1645 above; median age 2 years, range 6 months to
14 years). Between D0 and D28, Hb increased by +13.8%
(from 9.4 to 10.7 g/dl).
Haemoglobin levels changes between D0 and D3
On D3, Hb concentrations decreased −4.6% (95% CI -4.3%
to −4.9%), from 9.4 to 9.0 g/dl; such decrease was of −4.5%
(95% CI −.2% to −4.8%), from 9.3 to 8.9 g/dl, in patients
treated with ACT and −7% (95% CI -8.5%-5.6%) on AS.
The D3 drop in Hb was greater for subjects with normal
D0 Hb (from 11.9 to 10.8 g/dl, −9.3%, 95% CI -9.9% to
−8.6%) than for those who were anaemic (from 8.9 to
8.6 g/dl, −3.4%, 95% CI -3.7% to −3.0%, p = 0.001).
A multivariate logistic regression model with mixed-
effect showed that the risk was higher for patients with
higher D0 parasitaemia (AOR 2.51, 95% CI 2.23–2.83,
p = 0.001) and Hb (AOR 1.19, 95% CI 1.14–1.24,
p = 0.001) and lower for older subjects (AOR 0.87, 95% CI
0.83–0.92, p = 0.001), while no significant association was
found with parasitological failure (AOR 1.13, 95% CI 0.95–
1.34, p = 0.177) and treatment (all comparisons p > 0.1).
Time to haemoglobin nadir, children <5 years-old
Two studies enrolled 1645 children <5 years-old (median
age 2.3 years, range 0.5–4.9) in Liberia [19], Mozambique,
Rwanda, and Uganda [13] and recorded Hb on D0-D3,
D7, D14, D21, D28. D0 parasite density was 23,908 /μl
overall but varied across sites (p = 0.001). Median time-to-
nadir (Tn) was D2 Table 2), and was independent of treat-
ment (all comparisons p > 0.1). The predicted median Tn
calculated by linear regression was 35 h, ranging from
29 h with ASAQ in Uganda to 48 h with DP in Rwanda
(Additional file 6: Fig. S3).
The nadir occurred in 78% between D1–3, with the
highest proportion on D2 (34%). The highest rate of Hb
decrease (−12.6%) and slope (−1.25) were at D1. The
PRRd1 was highest (98.4%) for the patients whose Hb
increased post-D0 (HDRd1 + 8.3%) and lowest (83.8%) in
those with nadir at D3 (HDRd1–1.8%). Excluding the
11% subjects with no decrease, overall Hb dropped from
9.8 g/dl to 8.7 g/dl (−1.18 g/dl or - 11.4%, 95% CI -11.0%
to −11.8%, p = 0.001) (Table 2). The patterns of evolu-
tion of Hb levels are shown in Additional file 7: Fig. S4.
Subjects whose Hb increased after baseline (nadir on
D0) had significantly lower D0 parasitaemia (14,410 μl)
and Hb (9.0 g/dl) than those whose Hb decreased post-
D0 (parasite density = 25,403/μl; Hb = 9.9 g/dl, p = 0.001).
Subjects with higher D0 parasitaemia had longer Tn
(r = 0.281, p = 0.001, Spearman test); the correlation
between parasitaemia and Tn occurring between D1 and
D7 was also significant (r = 0.060, p = 0.021, Spearman
test) (Fig. 4). Tn was longer, and the drop in Hb greater, in
patients without D0 anaemia (mean Tn 3.0 days; Hb
change −14.7) than those presenting with anaemia (mean
Tn 2.1 days; Hb change −10.4%, p = 0.001). The PCT (but
not PRRd1) of patients whose Hb increased right after
treatment start was significantly faster (p = 0.001) than
that of patients with a decrease in Hb (whatever the time
to nadir); no difference was apparent for either parameters
between the groups with shorter and longer time to nadir.
Different approaches using linear regression mixed-
effect multivariate analyses produced consistent results,
whether the model includes the PRRd1, PCT or HDRd1.
The Hb percentage decrease at Tn was greater in subject
with higher D0 Hb and parasitaemia (p = 0.001) and
those with longer PCT (p = 0.001), and smaller in those
with higher PRRd1. A slight difference between models
was that the Hb percentage decrease was independent of
age when PRRd1 is used in the model (p = 0.088) but
lower in older patients (p = 0.010) when using PCT. It
was lower in patients treated with AL or DP than ASAQ
(p = 0.001 in all comparison except DP when using PCT,
p = 0.070).
Special attention was paid to the interaction between
Hb and parasitaemia at D1 (when on average ~ 93% of
the parasites were cleared – see Table 2). The rate at
which Hb fell (measured as Hb decrease rate from D0 to
D1, HDRd1) was slower in patients with longer Tn and
faster in patients with higher D0 Hb (p = 0.001). Con-
cerning parasitaemia, HDRd1 was higher in patients with
higher D0 parasitaemia (p = 0.001), and those with
longer PCT (p = 0.001), but was unrelated to PRRd1
(p = 0.112) and age (p = 0.296 and p = 0.124 in either
models). HDRd1 was less in patients treated with AL or
DP than with ASAQ (p = 0.001).
Haemoglobin recovery post-treatment
After an initial decrease in Hb concentrations, a + 19.4%
increase from D3 to D28 (from 8.9 to 10.7 g/dl) was ob-
served with a steady significant linear increment in Hb
of +0.065 g/dl/day throughout D28, i.e. +0.6% daily
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Fig. 4 Parasite density pre-treatment (D0) and time-to-nadir, children under 5 years old (Liberia, Mozambique, Rwanda, Uganda; n = 1645)
Fig. 5 Day 3 to Day 28, overall predicted trend and observed haemoglobin values according to anaemia status on admission, children under
15 years old (Burkina Faso, Gabon, Liberia, Mali, Mozambique, Nigeria, Rwanda, Uganda, Zambia, Zanzibar; n = 4886)
Equations
Overall: y = 0.065× + 9.1, p = 0.001
By anaemia status:
• anaemia on D0 y = 0.073× + 8.5, p = 0.001
• no anaemia on D0 y = 0.047× + 10.4, p = 0.001
By age (not shown):
• under 5’s y = 0.71× + 8.8, p = 0.001
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(Fig. 5). Patients with normal D0 Hb levels experienced
a significant slower recovery (+0.047 vs. +0.073 g/dl/day,
p = 0.001; corresponding to a daily Hb increase of +0.4%
and +0.7%, respectively) than those with pre-treatment
anaemia.
Linear regression mixed-effect model found that the
recovery in under 5’s was not significantly different from
the 5–15 years-old (p = 0.059), but that it was signifi-
cantly faster in patients with anaemia on D0 than those
without anaemia (p = 0.001). No between-treatment
difference was detected.
Discussion
While anaemia is a common feature of uncomplicated
falciparum malaria, studying anaemia during and after
malaria treatment is challenging because it is difficult to
disentangle the contributions of the infection itself, the
process of recovering from the disease, and drug-induced
adverse events. Furthermore, Hb is measured inconsist-
ently across antimalarial drug trials during treatment and
follow-up, and sometimes not often enough to describe
with sufficient precision the patterns of Hb changes.
Lastly, the definition and grades of anaemia may vary
across studies. All this calls for more standardised study
methodologies.
This analysis, representing a wide range of different
geographical areas of Sub-Saharan Africa (nine studies at
24 sites in 13 countries), concerns nearly 9000 patients
(of whom three-quarters are children under 5 years of
age) treated with either ACT or non-ACT for uncompli-
cated falciparum malaria. Although the frequency of sam-
pling during the study varied, Hb changes resulting in
anaemia could be studied during treatment and follow-up
and could be compared between treatments. Data were
analysed both as continuous (Hb concentration) and cat-
egorical variable (age-dependent presence and grade of
anaemia [22]), and risk factors for anaemia and drop in
Hb concentrations were assessed.
Anaemia risk on presentation with an acute uncomplicated
falciparum malaria episode
Anaemia was common in this largely paediatric patient
population: over two-thirds presented with anaemia, and
as many as 83% had at least one on-study Hb value
below the anaemia-defining cut-off.
Comparing these results between this dataset and other
published studies is difficult, as different cut-offs were
used to define anaemia and some studies report mean or
median Hb levels but not anaemia prevalence. Drawing
generalizable conclusions is further complicated by the
absence of information on background intensity of
transmission and other conditions which may cause Hb
to fall. For instance, considering recent studies, using
Hb <11 g/dl as the general cut-off, the prevalence of
anaemia was 36% in Mali in all-ages subjects with acute
malaria (n = 5990) with a geometric mean of ~18,000 para-
sites/μl [23]. When using haematocrit <30% (~Hb <10 g/dl)
in a cohort of 672 Nigerian <5’s with acute malaria, an-
aemia was found in 44% of subjects [24]. Other studies
report median Hb = 8.6 g/dl (>5000 children <11 years-
old, mean parasitaemia 9500 parasites/μl in Gabon)
[25]; mean Hb = 10.6 g/dl (>900 children <6 years-old,
mean parasitaemia ~40,000 parasites/μl in Mali) [26];
mean Hb =0.7 g/dl (~800 children <10 years-old, mean
parasitaemia 1250 parasites/μl in Zambia) [27]; mean
Hb = 9.9 g/dl - 10.4 g/dl (children <11 years-old, me-
dian parasitaemia ~14,000 parasites/μl in Cameroon)
[28]. Even within the present analysis we found wide
inter-country variations, with pre-treatment prevalence
of anaemia ranging from 2.3% (in Liberia where patients
had lower parasitaemia [19]) to 80.1% in Zanzibar, [21],
and mean pre-treatment Hb from 8.6 g/dl, Zanzibar [21]
to 12.9 g/dl in Liberia [19].
While malaria is known to cause anaemia, the extent
of Hb loss caused by each individual episode in not well
quantified. In a previous paper [29] we estimated this drop
to average 1.2 g/dl or 13% of a subject “normal status”.
Not unexpectedly, young age was found to be a risk
factor for anaemia on presentation with acute falciparum
malaria: compared to circa three-quarters of the under
5’s presented with anaemia, the relative risk was reduced
by half to two-thirds in older subjects. There was a signifi-
cant inverse correlation between parasitaemia and Hb
concentrations overall.
The fall and rise of haemoglobin
Hb drops soon after treatment starts to reach its nadir
(−4% to −6%) between D1-D3, thus supporting the use
of the latter as proxy for maximum Hb fall in the stand-
ard clinical trial. Thereafter Hb increases at a steady rate of
ca. 0.6% per day. Patients with normal D0 Hb levels experi-
ence a greater fall (−6% vs. -3.1%) and slower recovery
((+0.4% and +0.7% per day, respectively) than those with
pre-treatment anaemia. This study found no evidence of
delayed anaemia associated with oral artemisinin deriva-
tives, or any other treatment; in fact, the risk of anaemia
decreased with follow-up time.
This general trend hides three patterns of evolution of
Hb concentrations which become apparent in under 5’s
undergoing intense monitoring: (a) the dominant response
(~78%) is a decrease with the lowest Hb level recorded
between D1 and D3. This appears to be a fairly homoge-
neous population with D0 parasitaemia ~25,000 para-
sites/μl, PCT ~30 h [30], Hb 9.7–9.9 mg/dl, and drop
at nadir ~ −11.1 to −13.4%; (b) an additional 12% had
their Hb nadir at their D7 visit; they had higher pre-
treatment parasite counts (~30,000) and Hb (10.7 g/dl)
but their final Hb drop was only marginally greater
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(−13.8%); (c) in a further 11% of these patients Hb started
climbing immediately after treatment commenced (+8.3%
on D1); they had lower D0 parasite counts and Hb than
those whose Hb fell after treatment start. So, both pre-
treatment Hb and parasite counts were (b) > (a) > (c),
whereas the final Hb concentrations were (c) > (a) > (b).
Patients whose Hb started to increase immediately with
treatment cleared their parasites faster: the PCT was
(c) > (a) = (b).
How are these different patterns explained, and how
could they help us understand the relative effects on Hb
of uncomplicated falciparum malaria and antimalarial
treatment? We do not have all the elements to help us
draw definitive conclusions. For instance we do not
know how long had the patients been infected, and what
the time-course of their Hb level had been before they
came into observation. We know that malaria-induced
anaemia is accounted for not only by the destruction of
parasitized RBCs but also by the removal of uninfected
RBCs and by central effects on erythropoiesis. If already
on a downwards trend before treatment, Hb is therefore
expected to continue to fall because some of these
events will continue even when parasites are being killed
by the treatment. In fact, parasite killing accounts for a
small proportion of the Hb loss. Take for instance patients
whose nadir was on D1 (D0 parasitaemia = 23,221/μl;
PRRd1 = 95.4%, HDRd1–12.6%, Hb drop −1.27 g/dl), and
assuming the MCH (mean cell Hb) to be 25 picograms
(=2.5−11 g/RBC), a PRRd1 = 95.4% would translate in a loss
of 2.229 RBCs/dl and 0.055 Hb g/dl. This means that 96%
of the total 1.27 g/dl Hb drop is unaccounted for by para-
site killing (RBC destruction); this difference would remain
very large even after allowing for the biomass of seques-
tered parasites which are not seen in the peripheral circula-
tion. The total loss in RBCs (as calculated from the drop in
Hb) is approximately 20 times that accounted for by
parasite clearance. The early Hb drop and the absence
of delayed anaemia reported in cases of severe malaria
treated with artesunate [31], makes the contribution of
‘pitting’ (removal of ‘once-infected erythrocytes’ by the
spleen) in the case of uncomplicated malaria unlikely
or unimportant, possibly because of the relatively lower
parasite counts in uncomplicated malaria.
The malaria parasite is likely to determine the presence
and degree of anaemia both directly by the abovementioned
central and peripheral parasite effects, and also indirectly
for example by inducing, through generalised vasodilation
and internal fluid redistribution, complex changes in fluid
balance resulting in the reduction of the effective circulat-
ing blood volume [32], which are corrected during recov-
ery. It is therefore possible that, since what we measure is
concentrations and not absolute numbers, we have an
incomplete picture of the real situation in terms of both
anaemia on presentation and recovery post-treatment.
Our analyses point to a correlation between parasite
clearance and changes in Hb levels. Linear regression
mixed-effect multivariate analysis using different ap-
proaches concur to show that the degree of Hb loss
after treatment start is greater in patients with high
pre-treatment Hb and parasitaemia, is overall unrelated
to age, whether measured at D1 as Hb decrease rate
(HDRd1, approximately 24 h after treatment started) or
at the time of nadir as percentage decrease from pre-
treatment values. The drop in Hb levels is greater in
patients with slower parasite clearance and it is smaller
as percent reduction at nadir in those with higher para-
site clearance on D1. The early Hb fall seems therefore
to be more a question of slower onset of drug action
than it is of drug toxicity, is a short-term event, and is
independent of treatment ultimately succeeding or failing
or of patient’s age.
Conclusions
This study clarifies issues about risk factors of anaemia in
uncomplicated falciparum malaria before and after treat-
ment. It identifies risk factors on presentation (young age,
high parasitaemia), detects different patterns of responses
following antimalarial treatment (immediate increase, or
early or late decline followed by a linear increase afterwards
to restore normal Hb concentrations), shows that the ma-
jority of subjects experience a drop within 1–2 days (thus
earlier than commonly thought), and finds a relationship
between the degree of the early Hb dip and slower parasite
clearance. However, we still have an incomplete picture of
the overall interaction between malaria infection, antimal-
arial treatment and anaemia risk, especially when it comes
to the explaining the complex relationship between infec-
tion, treatment and haemoglobin.
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